Assessment of the impact of OCS use on 3 commonly used biomarkers in severe asthma, namely BEC, FeNO, and IgE, is critical for understanding asthma phenotypes and tailoring treatment strategies, especially in the context of biologic therapy. This evidence concerns the gene IGHE and asthma.